The Motion: PDE5 Inhibitors are a Promising Therapy for Benign Prostatic Hyperplasia

European Urology

Volumn 56, Issue 5, 2009, Pages 878-880

  McVary, Kevin ^a   Tubaro, Andreas ^b   De Nunzio, Cosimo ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; VARDENAFIL;

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION; SEXUAL HEALTH; COST CONTROL; DRUG COST; ECONOMICS; ENZYMOLOGY; EVIDENCE BASED MEDICINE; MALE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

COST CONTROL; COST-BENEFIT ANALYSIS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 70349273674     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.07.031     Document Type: Note

References (13)

1. K.T. McVary W. Monnig J.L. Camps J.M, Young Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma BJU Int 88 2007 100 103
2. C.G. Stief H. Porst D. Neuser M. Beneke E. Ulbrich A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
3. C. Roehrborn K.T. McVary A. Elion-Mboussa L. Viktrup Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228 1234
4. R.C. Roehrborn Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo controlled trial Urology 58 2001 953 959
5. B.T. Helfand R.M. Evans K.T. McVary Medical treatment of LUTS/BPH: Analysis of 8.7 million American men J Urol 181 2009 637 (abstract no. 1794)
6. P. Abrams L. Cardozo M. Fall The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 2 2002 167 178
7. K. Sairam E. Kulinskaya T.A. McNicholas G.B. Boustead D.C. Hanbury Sildenafil influences lower urinary tract symptoms BJU Int 90 2002 836 839
8. K.T. McVary W. Monnig J.L. Camps Jr J.M. Young Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 2007 1071 1077
9. J. McConnell P. Abrams L. Denis S. Khoury C.G. Roehrborn Male Lower Urinary Tract Dysfunction. Evaluation and Management. Paris France: Health Publications 2006
10. Oger S, Behr-Roussel D, Gorny D, et al. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol. In press. doi:10.1016/j.eururo.2009.04.039 .
11. H. Tinel B. Stelte-Ludwig J. Hutter P. Sandner Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms BJU Int 98 2006 1259 1263
12. R. Miano C. De Nunzio A.D. Asimakopoulos S. Germani A. Tubaro Treatment options for benign prostatic hyperplasia in older men Med Sci Monit 14 2008 RA94 102
13. Matthew 12:25 (King James Version).